Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of trastuzumab deruxtecan and afatinib in HER2-low advanced gastric cancer (VIKTORY-2)
KCT0009134Phase 2Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan, afatinib in gastric cancer (GC), sponsored by AstraZeneca. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecanafatinib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on KCT0009134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009134.